CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by yukon_goldon Oct 12, 2022 10:40pm

249 Views

Post# 35021300

Graycliff Webinar: The Makings of a New Ontario Gold Camp

Graycliff Exploration Presented

at a Webinar Hosted by Red Cloud:

Watch the Replay

Graycliff's President, CEO and Director James Macintosh spoke to Red Cloud's Mining Analyst Taylor Combaluzier about the Company's exploration efforts over four phases of drilling at the flagship Shakespeare Gold Project, including recent high-grade results and consistent presence of visible gold.

Watch the replay to learn more.